The Food and Drug Administration on Tuesday approved OraSure Technologies' rapid HIV antibody test for simultaneous screening for infection by both HIV-1 and HIV-2 subtypes of the virus. The test had previously been approved only to screen for HIV-1 infection, the strain of the virus most common in the United States. HIV-2 is common in West Africa. The combined screening allows for "broader detection, treatment, and prevention of HIV/AIDS," particularly in urban areas of the United States and in foreign countries, according to a press release from the company. The test can screen blood samples from finger sticks and venipuncture for HIV antibodies and produce results in about 20 minutes. The company is currently seeking FDA approval for the test to screen for HIV-1 and HIV-2 in oral fluids and blood plasma samples
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















